Industry Overview

Pharma Distribution & Licensing

Astellas Pharma sets up offices in India

Details: Category: Pharma Distribution & Licensing

Astellas Pharma, the Japan based global pharma player is setting up offices in India by investing Rs.160 million in its Indian arm ‘Astellas Pharma India Ltd”. It is strengthening its marketing and distribution system here to promote its products. It plans to introduce “Prograf”, a global leader in immunosuppressant used after organ transplantation. It has applied for approval from Indian DCGI.

Guradian Lifecare plans to add 100 retail pharma stores in India

Details: Category: Pharma Distribution & Licensing

Guradian Lifeceare, the retail pharmacy chain is planning to set up 100 stores in India by 2010 with an investment of Rs. 750 million. Currently, the company has 160 stores in operation with average size of its store at 600 sq.feet and empoys around 900 people. Indian market for retail pharma is pegged at Rs.330,000 million and expects to earn revenues of Rs.2500 million in this fiscal.

Ranbaxy to introduce new anti-hypertensive products in India

Details: Category: Pharma Distribution & Licensing

Ranbaxy Laboratories in collaboration with Daiichi Sankyo will introduce Olvance (Olmesartan, Medoxomil, antihypertensive) in India. This is a superior antihypertensive product and will offer excellent therapy option to doctors and patients in the country. The product is originally invented by the Japanese company Daiichi Sankyo and the first of the series of product of the agreement with Ranbaxy

Surya Pharma to venture into pharma retailing

Details: Category: Pharma Distribution & Licensing

Surya Pharma, Chandigarh based pharma company is planning to set up 500 pharma retail outlets with an investment of Rs. 2500 million. In the first phase, 100 stores will be opened up in National Capital Region and will be expanded to Chandigarh and Gurgaon later. Initially, the company will own the stores which areto be built on 150 to 1000 sq.ft will be owned then later will move to franchise models. The presence of spurious drug market and increasing affluence of customers to purchase healthcare products makes many pharma companies to venture into retailing